Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age.

Annals of internal medicine - 21 Aug 2018

Luoh Shiuh-Wen, Flaherty Keith T

Abstract excerpt

Matching unique features of cancer types with effective therapies is a cornerstone of precision medicine. Clinical success has been seen in inhibiting specific molecular alterations that drive the growth of cancer cells and targeting molecules whose elevated expression is confined to cancer cells. In addition, cancer cells can have vulnerabilities induced by somatic mutations they carry; attacks on these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasms
Share to Antineoplastic Agents, Immunological
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle Checkpoints

Share to Molecular Targeted Therapy

Share to Mutation

Share to Precision Medicine

Source

Identifiers

PMID: 30073297
DOI: 10.7326/M17-2832

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age.PMID 30073297Read ↗

If it's a target, it's a pan-cancer target: Tissue is not the issue.Semantic proximity Read ↗

Tissue-Agnostic Drug Development: A New Path to Drug ApprovalSemantic proximity Read ↗

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.Semantic proximity Read ↗

First Tissue-Agnostic Drug Approval IssuedSemantic proximity Read ↗

Moving pan-cancer studies from basic research toward the clinic.Semantic proximity Read ↗

The Future of Cancer Diagnosis and Treatment: Unlocking the Power of Biomarkers and Personalized Molecular-Targeted TherapiesSemantic proximity Read ↗

Tumors of the Digestive System: Comprehensive Review of Ancillary Testing and Biomarkers in the Era of Precision Medicine.Semantic proximity Read ↗

Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug DevelopmentSemantic proximity Read ↗

From Cancer Genomics to Precision Oncology—Tissue’s Still an IssueSemantic proximity Read ↗

Considering molecular alterations as pan-cancer tissue-agnostic targetsSemantic proximity Read ↗

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right GenomicsSemantic proximity Read ↗

Cancer immunotherapy: broadening the scope of targetable tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.